Inclusion Criteria:

• In order to be eligible to participate in this study, an individual must meet all of the following criteria:
• 1. Ability of subject to understand the study and stated willingness to comply with all study procedures and availability for the duration of the study.
• 2. Male or female, aged 18 years or older.
• 3. Able to speak and read English.
• 4. Willingness and ability to come to the NIA Clinical Research Unit at MedStar Harbor Hospital in Baltimore for study procedures.
• 5. Proof of positive SARS-CoV-2 testing exhibiting no current clinical symptoms.

Exclusion Criteria:

• An individual who meets any of the following criteria will be excluded from participation in this study:
• 1. Unable to verify identification of volunteer by state issued ID card, driver's license, or military ID. Participants earning greater than $600.00/year are issued a 1099 form, therefore, positive identification is required.
• 2. Unable to provide informed consent
• 3. Current use of steroids, immunosuppressive medications, radiation therapy, or chemotherapy medications.
• 4. Pregnancy.
• 5. Received immunization therapy for COVID-19 or have received a COVID-19 vaccination prior to Visit 1.
• In addition, eligible participants may not be immediately able to participate in the study but might be eligible at a later date. These include:
• 1. Symptoms of a viral infection on visit 1 (defer until resolved).
• 2. Medication: Volunteers taking the following medications would be deferred for 2 weeks after course has been completed and volunteer is feeling well: Antibiotics, antifungals, antimalarials, antvirals.
• 3. Temporary steroids (tapers): Deferred for 72 hours after symptoms are resolved and prescription is completed if taken orally, intravenously, or intramuscular. No deferral if taken intranasal, inhaled, or for joint injection.
• 4. Infection or Fever: Deferred until 2 weeks after antibiotics are completed and /or volunteer is feeling well.
• 5. We wish to only select recovered confirmed COVID-19 patients. Therefore, those who may have a household member (co-habitant) who is newly diagnosed with COVID-19 or who has symptoms will be deferred for 14 days.
• 6. Treatment with another investigational drug or other intervention within 14 days of visit 1 per the discretion of the Principal Investigator.